Date: 1st of July 2021 Your Name: Ebba Gløersen Müller Manuscript Title: Evaluation of semi-quantitative measures of ¹⁸F-Flutemetamol PET for the clinical diagnosis of Alzheimer's disease Manuscript number (if known): QIMS 21-188

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Civitan Norway Research Foundation for Alzheimer's disease	Unrestricted grant, payments made to my employer; Oslo University Hospital
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	xNone	
5	Payment or honoraria for	x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
0	testimony		
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x_None	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
10	Advisory Board	. Nega	
10	Leadership or fiduciary role in other board, society,	xNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	x_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	x_None	
	financial interests		

Ebba Gløersen Müller has through Oslo University Hospital received unrestricted grant from Civitan Norway Research Foundation for Alzheimer's disease to support the PhD.

Please place an "X" next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 2/7-21 Your Name: Caroline Stokke Manuscript Title: Evaluation of semi-quantitative measures of ¹⁸F-Flutemetamol PET for the clinical diagnosis of Alzheimer´s disease Manuscript number (if known): QIMS 21-188

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
Ū	pending		
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
- 10			
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

_x_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 01.07.2021 Your Name: Henning Langen Stokmo Manuscript Title: Evaluation of semi-quantitative measures of ¹⁸F-Flutemetamol PET for the clinical diagnosis of Alzheimer's disease Manuscript number (if known): QIMS 21-188

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	Siemens Healthineers	Payments made to me

5	Payment or honoraria for	_X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N. Norse	
6	Payment for expert testimony	_X_None	
	testimony		
7	Support for attending	X None	
'	meetings and/or travel		
8	Patents planned, issued or	_X_None	
	pending		
9	•	_X_None	
	Safety Monitoring Board or		
10	Advisory Board	V Neze	
10	Leadership or fiduciary role in other board, society,	_X_None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
15	financial interests		

I have received consultancy fees from Siemens Healthineers.

Please place an "X" next to the following statement to indicate your agreement:

_X_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 03-07-2021 Your Name: Trine Holt Edwin Manuscript Title: Evaluation of semi-quantitative measures of ¹⁸F-Flutemetamol PET for the clinical diagnosis of Alzheimer's disease Manuscript number (if known): QIMS 21-188

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None The Norwegian Health Association	The payments were made to Norwegian National Advisory Unit on Ageing and Health
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
З	Royalties or licenses	xNone	

4	Consulting fees	x_None	
5	Payment or honoraria for	x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
Ū	testimony		
7	Support for attending meetings and/or travel	x_None	
	<i>U i</i>		
8	Patents planned, issued or	x_None	
	pending		
_			
9	Participation on a Data	xNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	x None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
4.0			
12	Receipt of equipment, materials, drugs, medical	x_None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests	Roche BN29553	A rater, outside the submitted work
		Boeringer-Ingelheim 1346.0023	A rater, outside the submitted work

Trine Holt Edwin has been a rater in, two clinical trials (Roche BN29553 and Boeringer-Ingelheim 1346.0023), outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 2 July 2, 2021 Your Name: Anne-Brita Knapskog Manuscript Title: Evaluation of semi-quantitative measures of ¹⁸F-Flutemetamol PET for the clinical diagnosis of Alzheimer's disease Manuscript number (if known): QIMS 21-188

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated	Norwegian Health	Postdoc grant through Oslo University Hospital
	in item #1 above).	Association	
3	Royalties or licenses	x_None	
4	Consulting fees	_xNone	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events XNone 6 Payment for expert testimony XNone 7 Support for attending XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events	
Iectures, presentations, speakers bureaus, manuscript writing or educational events	
speakers bureaus, manuscript writing or educational events	
manuscript writing or educational events	
educational events	
6 Payment for expert testimony x_None 7 Support for attending x_None	
testimony	
7 Support for attending xNone	
meetings and/or travel	
8 Patents planned, issued orx_None	
pending	
9 Participation on a Data	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role x None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options _xNone	
12 Receipt of equipment,xNone	
materials, drugs, medical	
materials, drugs, medical	
materials, drugs, medical writing, gifts or other services	
materials, drugs, medical writing, gifts or other services	

2016-2019 National coordinator, Boehringer-Ingelheim (1346.0023). 2017-2019 Principal investigator site , Roche (BN29553) 2021-2025 Principal investigator site, Novo Nordisk, EVOKE (NN6535-4730)

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: July 1st 2021 Your Name: Mona-Elisabeth Revheim Manuscript Title: Evaluation of semi-quantitative measures of ¹⁸F-Flutemetamol PET for the clinical diagnosis of Alzheimer´s disease Manuscript number (if known): QIMS 21-188

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Civitan Norway Research Foundation for Alzheimer's disease	Unrestricted grant to Oslo University Hospital
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending	_xNone	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x_None	
12	Receipt of equipment,	x_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_xNone	
	financial interests		

Mona Elisabeth Revheim has received unrestricted grants from Civitan Norway Research foundation for Alzheimer's disease.

Please place an "X" next to the following statement to indicate your agreement:

__x_I certify that I have answered every question and have not altered the wording of any of the questions on this form.